Polaroid Therapeutics achieves pre-clinical milestones for superior antimicrobial technology

Polaroid Therapeutics, a Swiss-based biotech start-up, has reached significant pre-clinical milestones in the development of its innovative medical device aimed at enhancing patient outcomes in wound care. The company is utilizing a proprietary antimicrobial polymer technology that effectively reduces bacterial bioburden without triggering antimicrobial resistance (AMR), which is a major global public health threat.

The misuse and overuse of antimicrobials, such as antibiotics, contribute to the development of AMR. When bacteria, viruses, fungi, and parasites adapt to these treatments due to excessive or inappropriate use, they become less effective over time. The World Health Organization has identified AMR as one of the top global public health and development threats, with bacterial AMR directly responsible for 1.27 million global deaths in 2019 and contributing to 4.95 million deaths.

With the Advanced Wound Dressing (AWD) market valued at 4.5 billion USD and witnessing increasing demand and technological advancements, Polaroid Therapeutics aims to collaborate with industry leaders to further develop and commercialize their antimicrobial technology. Chronic wounds are a significant issue, affecting 1-2% of the global population each year. As the global population continues to age, the number of affected patients is expected to increase, highlighting the need for effective chronic wound management strategies.

In addition to improving patient outcomes, prioritizing effective treatment strategies for chronic wounds can optimize healthcare resources and contribute to a more efficient and sustainable healthcare system globally.

The AWD market is projected to expand at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030, with antimicrobial products representing a significant portion of the market. This presents an opportunity for Polaroid Therapeutics and its partners to capitalize on superior product development and a patient-centric approach to enhance patient outcomes.

Ran Frenkel, CEO and Co-Founder of Polaroid Therapeutics, emphasized the company’s mission to address the unmet medical needs in wound care and provide effective solutions on a global scale. Polaroid Therapeutics, incubated and spun off by the iconic Polaroid brand, aims to bring to life the vision of creating a more human and meaningful world through cutting-edge technology and research.

For more information about Polaroid Therapeutics and its innovative antimicrobial technology, please visit their website.

Table: Global Advanced Wound Dressing Market

Year Market Value (USD) Annual Growth Rate
2022 4.5 billion N/A
2023 TBD 4.5%
2024 TBD TBD

2030 TBD TBD

Note: The market value and growth rate data for 2023 onwards are projections and subject to change.

[1] World Health Organization
[2] Lindholm, C. and Searle, R. (2016) ‚Wound management for the 21st century: combining effectiveness and efficiency,‘ International Wound Journal, 13(S2), pp. 5–15.
[3] Source: BioMedGPS© 2022 Global Advanced Wound Dressing www.smarttrak.com

Quelle: Polaroid Therapuetics‘ / ots

Ähnliche Artikel

Schreibe einen Kommentar

Deine E-Mail-Adresse wird nicht veröffentlicht. Erforderliche Felder sind mit * markiert

Schaltfläche "Zurück zum Anfang"